SPRY

ARS Pharmaceuticals Inc

Jun 12 • 04:00PM ET

9.76

+0.17 1.77 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: HRMY SUPN ALKS PRGO BHC AMRX INDV LNTH TEVA VTRS

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO SMLF VHT

Index	RUT	P/E	-	EPS (ttm)	-2.00	Insider Own	35.05%	Shs Outstand	99.30M	Perf Week	14.02%
Market Cap	969.20M	Forward P/E	-	EPS next Y	-0.96	Insider Trans	-0.08%	Shs Float	64.50M	Perf Month	21.85%
Enterprise Value	864.75M	PEG	-	EPS next Q	-0.48	Inst Own	74.28%	Short Float	39.53%	Perf Quarter	16.33%
Income	-197.98M	P/S	9.79	EPS this Y	-0.57%	Inst Trans	-1.02%	Short Ratio	15.05	Perf Half Y	-6.51%
Sales	98.99M	P/B	15.81	EPS next Y	45.37%	ROA	-64.39%	Short Interest	25.50M	Perf YTD	-16.22%
Book/sh	0.62	P/C	4.82	EPS next 5Y	-	ROE	-136.40%	52W High	18.90 -48.36%	Perf Year	-32.22%
Cash/sh	2.02	P/FCF	-	EPS past 3/5Y	-26.04% -12.85%	ROIC	-125.44%	52W Low	6.66 46.55%	Perf 3Y	56.04%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	300.09% -	Gross Margin	74.12%	Volatility	6.89% 7.41%	Perf 5Y	-70.63%
Dividend TTM	-	EV/Sales	8.74	EPS Y/Y TTM	-1130.30%	Oper. Margin	-204.49%	ATR (14)	0.60	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.77	Sales Y/Y TTM	1.92%	Profit Margin	-200.00%	RSI (14)	61.60	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.94	EPS Q/Q	-76.39%	SMA20	13.01%	Beta	0.90	Target Price	28.80
Payout	-	Debt/Eq	1.57	Sales Q/Q	184.47%	SMA50	15.58%	Rel Volume	0.78	Prev Close	9.59
Employees	163	LT Debt/Eq	1.57	Earnings	May 15 BMO	SMA200	3.45%	Avg Volume	1.69M	Price	9.76
IPO	Dec 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.22% 2.17%	Trades		Volume	1,323,368	Change	1.77%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-26	Initiated	Northland Capital	Outperform	$25
Nov-04-25	Resumed	Roth Capital	Buy	$30
Sep-04-25	Initiated	Roth Capital	Buy	$40
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$30
Feb-10-25	Initiated	Oppenheimer	Outperform	$40
Aug-20-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Upgrade	Raymond James	Outperform → Strong Buy	$18 → $22
Aug-12-24	Reiterated	Leerink Partners	Outperform	$19 → $20
Jul-25-24	Initiated	Raymond James	Outperform	$18
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform	$6 → $18
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform	$10
Jan-03-23	Initiated	William Blair	Outperform	$17
Dec-13-22	Initiated	SVB Leerink	Outperform	$14

Show Previous Ratings

Jun-04-26 08:00AM	Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies (GlobeNewswire)
May-16-26 08:30AM	ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby)
May-15-26 07:01PM	ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) -6.49%
06:00AM	ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
May-13-26 08:00AM	ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President (GlobeNewswire) -7.18%
08:00AM	Loading…
May-07-26 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results (GlobeNewswire)
Apr-15-26 06:05AM	neffy (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Mar-27-26 08:00AM	ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg (epinephrine nasal spray) Label (GlobeNewswire) -5.72%
Mar-09-26 03:01PM	ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... (GuruFocus.com)
07:10AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
06:00AM	ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization (GlobeNewswire)
Mar-06-26 07:15AM	What To Expect From ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings (GuruFocus.com)
Mar-02-26 12:23PM	Canadian Natural to Report Q4 Earnings: What's in the Offing? (Zacks)
10:00AM	ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-23-26 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences (GlobeNewswire)
08:00AM	Loading…
Feb-10-26 08:00AM	ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting (GlobeNewswire)
Feb-02-26 01:12PM	What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment? (Benzinga)
Jan-21-26 08:00AM	California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use (GlobeNewswire)
Jan-09-26 12:32PM	Bad News For Competitor Turns Into Big Win For ARS Pharma Stock (Benzinga) +19.27%
11:28AM	Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application (Benzinga)
03:16AM	ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating (Insider Monkey)
Dec-30-25 08:10AM	ARS Pharmaceuticals announces NMPA approval for neffy 2 mg (TipRanks)
Dec-29-25 08:00AM	neffy (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Nov-26-25 08:00AM	ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-10-25 04:01PM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
07:05AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:00AM	ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-07-25 07:19AM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +7.99%
Nov-06-25 09:10AM	Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -9.45%
Nov-05-25 09:15AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
09:35AM	Loading…
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	ARS Pharma Launches Get neffy on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-03-25 02:23PM	UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results (GlobeNewswire)
07:45AM	ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-08-25 08:00AM	ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy (epinephrine nasal spray) (GlobeNewswire) +7.55%
Sep-29-25 04:05PM	ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy (GlobeNewswire)
Sep-19-25 08:00AM	neffy (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Sep-17-25 11:44AM	ARS Pharmaceuticals, Inc. (SPRY): A Bull Case Theory (Insider Monkey)
Sep-09-25 08:11AM	ARS Pharmaceuticals announces real-world evidence on neffy effectiveness (TipRanks)
Sep-08-25 08:00AM	Real-World Evidence Supports Clinical Effectiveness of neffy (epinephrine nasal spray) in Patients Experiencing Anaphylaxis (GlobeNewswire) +6.26%
Sep-04-25 02:54PM	ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA (Insider Monkey)
Aug-28-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-25 08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.04%
07:00AM	ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy (epinephrine nasal spray) (GlobeNewswire)
05:26AM	Cisco Systems headlines earnings slate (MarketWatch)
Aug-12-25 09:24AM	ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-11-25 06:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -6.40%
Aug-08-25 01:56PM	Paramount, Rocket, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-04-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 05:35PM	Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates (Zacks)
08:50AM	Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength (Zacks)
Jul-30-25 10:00AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-29-25 10:00AM	Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-18-25 12:27PM	MHRA approves needle-free adrenaline nasal spray for anaphylaxis (Pharmaceutical Technology)
09:25AM	EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Jul-15-25 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? (Zacks)
09:55AM	Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? (Zacks)
08:50AM	What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' (Zacks)
Jun-15-25 05:26AM	Jim Cramer on ARS Pharmaceuticals: "It's a Great Flier" (Insider Monkey)
Jun-11-25 09:02PM	Lightning Round: I don't want to buy enterprise software right now, says Jim Cramer (CNBC TV)
May-27-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-25 03:12AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ... (GuruFocus.com)
May-14-25 10:44PM	Q1 2025 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.36%
08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy (epinephrine nasal spray) (GlobeNewswire)
May-13-25 09:28AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:06AM	ARS Pharmas epinephrine nasal spray 1mg now available in US (Pharmaceutical Technology)
May-05-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results (GlobeNewswire)
May-04-25 04:32PM	Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential (Seeking Alpha)
May-02-25 08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
Apr-30-25 06:51AM	ARS Pharmaceuticals Has A Blockbuster Candidate (Seeking Alpha)
Apr-05-25 05:31PM	ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Mar-23-25 07:18AM	Wall Street Week Ahead (SeekingAlpha)
Mar-21-25 12:16PM	Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz (TipRanks) -13.63%
12:03PM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
03:03AM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
12:40AM	Q4 2024 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 04:04PM	ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. (Investor's Business Daily) +22.83%
03:31PM	ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await (SeekingAlpha)
01:29PM	ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion (SeekingAlpha)
01:28PM	ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript (SeekingAlpha)
08:25AM	ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-06-25 05:27AM	FDA approves ARS neffy 1mg for paediatric anaphylaxis (Pharmaceutical Technology)
Mar-03-25 04:35PM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences (GlobeNewswire)
Feb-20-25 07:02PM	ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients (GlobeNewswire)
Feb-18-25 08:00AM	ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting (GlobeNewswire)
Feb-05-25 08:00AM	ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference (GlobeNewswire)
Jan-21-25 08:00AM	ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools (GlobeNewswire) +7.24%
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily)
08:00AM	ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy (epinephrine nasal spray) (GlobeNewswire)
Jan-07-25 08:15AM	ARS Pharmaceuticals files for approval of neffy in Canada, U.K. (TipRanks)
06:43AM	ARS Pharma seeks approval for epinephrine spray in Canada and UK (Medical Device Network)
Jan-06-25 08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abello A/S (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abell A/S (GlobeNewswire)
Dec-19-24 05:25PM	ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies (GlobeNewswire)
Dec-18-24 08:00AM	ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.80%
Dec-12-24 02:32PM	ARS Pharmaceuticals Announces Filings for Approval of neffy in China, Japan and Australia (GlobeNewswire)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

M.D.Dr. Sarina Tanimoto M.B.A.

Chief Business OfficerMr. Justin Chakma

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Karas Eric	Chief Commercial Officer	Jun 12 '26	Option Exercise	1.50	25,000	37,500	37,176	Jun 12 08:06 PM
Karas Eric	Chief Commercial Officer	Jun 12 '26	Sale	10.00	25,000	250,000	12,176	Jun 12 08:06 PM
Fitzpatrick Alexander A	Chief Legal Officer	Jun 12 '26	Sale	10.00	3,355	33,550	90,910	Jun 12 08:04 PM
ERIC KARAS	Officer	Jun 12 '26	Proposed Sale	10.00	25,000	250,000		Jun 12 04:31 PM
ALEXANDER FITZPATRICK	Officer	Jun 12 '26	Proposed Sale	10.00	3,355	33,550		Jun 12 04:17 PM
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Option Exercise	0.64	21,828	13,970	32,617	Nov 14 06:43 PM
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Sale	8.71	21,828	190,050	10,789	Nov 14 06:43 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Option Exercise	0.84	30,000	25,200	166,380	Nov 14 06:42 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Sale	8.87	166,380	1,476,147	0	Nov 14 06:42 PM
BRIAN T DORSEY	Officer	Nov 13 '25	Proposed Sale	8.71	21,828	190,050		Nov 13 04:08 PM
JUSTIN CHAKMA	Officer	Nov 12 '25	Proposed Sale	8.91	30,000	267,357		Nov 12 05:26 PM
Chakma Justin	Officer	Nov 12 '25	Proposed Sale	8.87	138,380	1,227,420		Nov 12 10:56 AM
Lowenthal Richard E	PRESIDENT AND CEO	Aug 21 '25	Sale	14.49	50,000	724,345	1,196,494	Aug 22 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Aug 21 '25	Option Exercise	1.50	12,500	18,750	22,542	Aug 22 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Aug 21 '25	Sale	15.00	12,500	187,500	10,042	Aug 22 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 20 '25	Sale	14.09	37,656	530,626	1,247,447	Aug 21 05:36 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 19 '25	Sale	14.03	12,344	173,130	1,285,103	Aug 21 05:36 PM
KATHLEEN D SCOTT	Officer	Aug 21 '25	Proposed Sale	15.00	12,500	187,500		Aug 21 04:18 PM
Lowenthal Richard E	Officer	Aug 21 '25	Proposed Sale	14.15	150,000	2,123,000		Aug 21 11:20 AM
Tanimoto Sarina	Officer	Aug 19 '25	Proposed Sale	14.00	150,000	2,100,000		Aug 19 10:22 AM
Karas Eric	Chief Commercial Officer	Jul 01 '25	Option Exercise	1.50	15,000	22,500	25,315	Jul 03 04:21 PM
Karas Eric	Chief Commercial Officer	Jul 01 '25	Sale	16.99	15,000	254,860	10,315	Jul 03 04:21 PM
Flynn James E	10% Owner	Jun 27 '25	Sale	18.46	740,149	13,663,151	4,887,254	Jul 01 04:42 PM
ERIC KARAS	Officer	Jul 01 '25	Proposed Sale	16.99	15,000	254,859		Jul 01 04:20 PM
Karas Eric	Chief Commercial Officer	Jun 18 '25	Option Exercise	1.50	15,000	22,500	22,696	Jun 20 06:38 PM
Karas Eric	Chief Commercial Officer	Jun 18 '25	Sale	16.00	15,000	240,000	7,696	Jun 20 06:38 PM
ERIC KARAS	Officer	Jun 18 '25	Proposed Sale	16.00	15,000	240,000		Jun 18 04:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRY

ARS Pharmaceuticals Inc

Upgrade your Finviz experience